- Report
- January 2024
- 175 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- February 2024
- 250 Pages
Global
From €4856EUR$5,000USD£4,189GBP
- Report
- June 2022
- 215 Pages
United States
From €2621EUR$2,699USD£2,261GBP
- Report
- June 2021
- 195 Pages
United States
From €2428EUR$2,500USD£2,095GBP
- Report
- October 2019
- 310 Pages
Global
From €3351EUR$3,450USD£2,891GBP
- Report
- June 2019
- 220 Pages
Global
From €2127EUR$2,190USD£1,835GBP
- Report
- August 2022
- 120 Pages
Global
From €4371EUR$4,500USD£3,770GBP
Infanrix is a brand of vaccines used to protect against a range of infectious diseases. It is a combination vaccine, meaning it contains multiple antigens in a single dose. It is typically administered to infants and young children, and is available in both injectable and oral forms. The vaccine is designed to protect against diphtheria, tetanus, pertussis, hepatitis B, and poliomyelitis. It is also available in combination with other vaccines, such as Haemophilus influenzae type b (Hib) and inactivated polio virus (IPV).
Infanrix is widely used in many countries around the world, and is recommended by the World Health Organization (WHO). It is also approved by the US Food and Drug Administration (FDA).
Some companies in the Infanrix market include GlaxoSmithKline, Sanofi Pasteur, Merck, Pfizer, and Novartis. Show Less Read more